What's Happening?
C2N Diagnostics has received a laboratory permit from the New York State Department of Health, allowing it to offer its PrecivityAD2 and PrecivityAD blood tests for Alzheimer's disease diagnosis across
New York. These tests detect amyloid plaques in the brain, aiding healthcare professionals in making informed treatment decisions. The permit expands the availability of these tests to all 50 states, Washington D.C., Puerto Rico, and select international locations.
Why It's Important?
The approval from New York State represents a significant milestone for C2N Diagnostics, enhancing access to early and accurate Alzheimer's disease diagnosis. With the availability of disease-modifying therapies, early detection through these blood tests can lead to better patient outcomes and management. This development is crucial for the growing older population, providing a convenient and affordable diagnostic tool that supports timely medical intervention and lifestyle adjustments.
What's Next?
C2N Diagnostics plans to continue expanding its diagnostic capabilities and collaborate with healthcare providers to integrate these tests into routine clinical practice. The company is also pursuing FDA review for its multi-analyte algorithmic blood test, which could further enhance diagnostic accuracy. Ongoing research and partnerships aim to improve global public health by advancing Alzheimer's disease diagnostics and treatment.
